About NANO MRNA

Happy New Year

I hope the New Year finds all of you in good health and happiness.

Last year, we pivoted to the new business model of mRNA drug discovery, and changed our company name accordingly, adopting NANO MRNA Co., Ltd.

On the R&D front, we are pursuing the partnering and enhancement of R&D talent that will drive mRNA drug discovery. Meanwhile our drug discovery activities have successfully launched and been in full operation, and in addition to our alliance with Kao, our newly established mRNA IPG Unit is already producing and starting projects based on new ideas. In 2024 as our IP generation model enters its second year, we will ensure that intellectual property (IP) rights are secured in connection with those efforts, while leveraging collaborations and other activities as multiplier to enhance new seeds. With the IP creation cycle leading to the ongoing creation of IPs going forward, we will step up to a new level, aiming to become a first-tier company in terms of mRNA drug creation capabilities.

Regarding the RUNX1 mRNA, we are making progress in consultations with regulatory authorities towards the start of investigator-initiated clinical trials, and in this process have rapidly gained a wealth of expertise that will benefit the future research and development of mRNA drugs. The investigator-initiated clinical trial of TUG1 ASO is also about to begin. TUG1 ASO has potential as a new therapeutics for intractable cancer, and we believe that this clinical trial steady progress will also make steady progress. We will pursue out-licensing activities in parallel with these efforts.

We truly appreciate your continued support for our activities.

Last but not least, I sincerely wish you all have a wonderful New Year.

Sincerely yours,